WB
URGN icon

WesBanco Bank’s UroGen Pharma URGN Stock Holding History

WesBanco Bank’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,400
Closed -$823K – 665
2025
Q1 		$823K Hold
74,400
– – 0.03% 351
2024
Q4 		$792K Hold
74,400
– – 0.03% 352
2024
Q3 		$945K Buy
+74,400
New +$1.1M 0.03% 332

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

WesBanco Bank's URGN Position: Q2 2025 in Review

WesBanco Bank sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 74,400 shares — an estimated $823K sold.

WesBanco Bank first reported a position in URGN in Q3 2024 and held it in 3 quarters. The position peaked at $945K in Q3 2024. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • WesBanco Bank reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • WesBanco Bank sold 74,400 UroGen Pharma shares in Q2 2025, an estimated $823K.
  • WesBanco Bank first reported a position in UroGen Pharma in Q3 2024 and held it in 3 quarters.
  • WesBanco Bank's UroGen Pharma position peaked at $945K in Q3 2024.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on WesBanco Bank's 13F filing for Q2 2025, filed 7 Jul 2025.